The clinical outcomes of rituximab biosimilar CT-P10 (Truxima(R)) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience

  • Lee, Kyoungmin; 
  • Ha, Joo Young; 
  • Jung, Ah Ra; 
  • Lee, Yoon Sei; 
  • Lee, Sang-wook; 
  • 외 7명
Citations

WEB OF SCIENCE

16
Citations

SCOPUS

19

초록

This research was funded by the National Research Foundation of Korea, grant numbers MSIP; 2019R1H1A1080141 awarded to Y.S.L. Medical editing support (including copyediting) was provided by Beatrice Tyrrell, DPhil at Aspire Scientific (Bollington, UK) and funded by Celltrion Healthcare Co., Ltd (Incheon, Republic of Korea).

키워드

Diffuse large B-cell lymphoma; biosimilar; rituximab; CT-P10; Truxima(R); real-world evidence; R-CHOP; PLUS CYCLOPHOSPHAMIDE; FOLLICULAR LYMPHOMA; PARALLEL-GROUP; DOUBLE-BLIND; EFFICACY; PHARMACOKINETICS; CLASSIFICATION; CHEMOTHERAPY; VINCRISTINE
제목
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima(R)) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience
저자
Lee, Kyoungmin; Ha, Joo Young; Jung, Ah Ra; Lee, Yoon Sei; Lee, Sang-wook; Ryu, Jin-Sook; Chae, Eun Jin; Kim, Kyung Won; Huh, Jooryung; Park, Chan-Sik; Yoon, Dok Hyun; Suh, Cheolwon
DOI
10.1080/10428194.2020.1742906
발행일
2020-06
유형
Article; Early Access
저널명
Leukemia and Lymphoma
권
61
호
7
페이지
1575 ~ 1583